

Lonza Obtains Order Preventing Infringement of Its Patents Covering the Cocoon® Platform

- On January 21, 2022, a United States federal district court entered a preliminary injunction preventing infringement of Lonza's patents related to its innovative Cocoon® Platform
 - Adva Biotechnology Ltd. is enjoined from making, using, selling, offering to sell, and importing into the United States the Adva X3 system pending resolution of the case
-

Basel, Switzerland, 25 January 2022 – On January 21, 2022, in the United States District Court for the District of Maryland, Lonza, a leading global cell and gene therapy manufacturer, obtained a preliminary injunction against Adva Biotechnology Ltd. ("Adva") preventing Adva from importing and offering their Adva X3 device in the United States pending resolution of the case.

On October 23, 2020, Lonza brought suit against Adva, alleging Adva's infringement of Lonza and their affiliate Octane Biotech Inc.'s patents covering the innovative Cocoon® Platform. The Cocoon® Platform is an automated and closed platform for patient-scale cell therapy manufacturing, designed to overcome manufacturing challenges associated with patient-scale personalized medicines. The Cocoon® Platform is commercially available and gaining global traction as the go-to manufacturing platform for patient-scale cell therapies.

According to Lonza's court filings, Adva's system—the ADVA X3—infringes Lonza and Octane Biotech Inc.'s patents including U.S. Patent Nos. 10,844,338; 10,723,986; 9,783,768; 9,701,932; 9,534,195; 9,499,780; and 8,492,140. Details of the case can be found at case number 8:20-cv-03099-PX. With this order, Lonza further demonstrates its position as a leading innovator in the cell therapy manufacturing market and will continue to provide its leading solutions to therapy developers and ultimately to patients.

As a leading innovator in the pharmaceutical and biologics manufacturing industry, Lonza has many patents covering their innovative offerings.

For more information on Lonza's patent portfolio please visit www.lonza.com/ip.

About Lonza

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 15,000 full-time employees, we comprise high-performing teams and individual talent that make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 2.5 billion with a CORE EBITDA of CHF 847 million in H1 2021. Find out more at www.lonza.com.

Follow @Lonza on [LinkedIn](#)

Follow @LonzaGroup on [Twitter](#)

Lonza Contact Details

Victoria Morgan

Head of External Communications

Lonza Group Ltd

Tel +41 61 316 2283

victoria.morgan@lonza.com

Dirk Oehlers

Investor Relations

Lonza Group Ltd

Tel +41 61 316 8540

dirk.oehlers@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.